FDA Clearance Tracker · P000021-S013
DIMENSION VISTA TPSA FLEX REAGENT CARTRIDGE
Last checked: Nov 20, 2026Latest source record: May 19, 2010 (this decision)Source: openFDAMethods & limitations
Decided
May 19, 2010
Approved
Time to decision
533 days
Received Dec 2, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P000021-S013
- Device name
- DIMENSION VISTA TPSA FLEX REAGENT CARTRIDGE
- Applicant
- Siemens Healthcare Diagnostics
- Applicant location
- Newark, DE
- Received
- Dec 2, 2008
- Decided
- May 19, 2010
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P000021
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE FOLLOWING CHANGES:1) DETECTION TECHNOLOGY FROM SPECTROPHOTOMETRY TO CHEMILUMINESENCE2) APPROPRIATE REAGENT PROCESS CHANGES TO ACCOMMODATE CHEMILUMINESENCE DETECTION3) USAGE ON THE DIMENSION VISTA 1500 SYSTEM4) USAGE ON THE DIMENSION VISTA 3000T SYSTEM WHICH CONSISTS OF TWO DIMENSION VISTA1500 SYSTEMS CONNECTED BY A SAMPLE TRACK TRANSPORT MECHANISM5) USAGE ON THE DIMENSION VISTA 1500 SYSTEM CONNECTED TO THE STREAMLAB ANALYTICALWORKCELL LABORATORY AUTOMATION SYSTEM6) THE NEW DIMENSION VISTA PSA CALIBRATOR FOR USE WITH THE DIMENSION VISTA TPSA AND FPSA METHODS.THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME DIMENSION VISTA TPSA FLEXREAGENT CARTRIDGE AND IS INDICATED FOR THE FOLLOWING USES:THE TPSA METHOD IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUANTITATIVE MEASUREMENT OF TOTAL PROSTATESPECIFIC ANTIGEN (PSA) IN HUMAN SERUM AND PLASMA ON THE DIMENSION VISTA SYSTEM: 1) AS AN AID IN THE DETECTION OF PROSTATE CANCER WHEN USED IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) IN MEN 50 YEARS OR OLDER. PROSTATE BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. 2) AS AN AID IN THEMANAGEMENT (MONITORING) OF PROSTATE CANCER PATIENTS.THE DIMENSION VISTA PSA CALIBRATOR WILL BE MARKETED SEPARATELY FOR USE WITH THE DIMENSIONVISTA TPSA FLEX REAGENT AND IS INDICATED FOR THE CALIBRATION OF TOTAL (TPSA) AND FREE (FPSA) PROSTATE SPECIFIC ANTIGEN METHODS ON THE DIMENSION VISTA SYSTEMS.
Source documents
Other decisions for Siemens Healthcare Diagnostics
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.